Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracellular Signaling Peptides and Proteins | 17 | 2024 | 278 | 2.170 |
Why?
|
| Intestinal Mucosa | 6 | 2020 | 186 | 0.760 |
Why?
|
| Neoplastic Stem Cells | 9 | 2020 | 138 | 0.730 |
Why?
|
| Pancreatic Neoplasms | 5 | 2020 | 516 | 0.690 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2020 | 133 | 0.680 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 377 | 0.670 |
Why?
|
| Colitis | 2 | 2018 | 53 | 0.630 |
Why?
|
| Gene Deletion | 2 | 2015 | 116 | 0.590 |
Why?
|
| MicroRNAs | 7 | 2024 | 281 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 445 | 0.550 |
Why?
|
| Whole-Body Irradiation | 4 | 2016 | 38 | 0.540 |
Why?
|
| Epithelial Cells | 8 | 2018 | 241 | 0.530 |
Why?
|
| Dextran Sulfate | 1 | 2015 | 9 | 0.500 |
Why?
|
| Colon | 2 | 2018 | 119 | 0.500 |
Why?
|
| Stem Cells | 6 | 2016 | 113 | 0.490 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 164 | 0.490 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 24 | 0.480 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 116 | 0.480 |
Why?
|
| Receptors, Notch | 2 | 2014 | 44 | 0.470 |
Why?
|
| Mice | 19 | 2020 | 4472 | 0.440 |
Why?
|
| Signal Transduction | 5 | 2018 | 1379 | 0.440 |
Why?
|
| Cell Proliferation | 10 | 2020 | 774 | 0.420 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 626 | 0.390 |
Why?
|
| Inflammation | 4 | 2024 | 608 | 0.390 |
Why?
|
| Histones | 1 | 2012 | 90 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 7 | 2018 | 110 | 0.380 |
Why?
|
| Animals | 23 | 2020 | 10078 | 0.370 |
Why?
|
| Alternative Splicing | 2 | 2020 | 44 | 0.320 |
Why?
|
| Apoptosis | 5 | 2018 | 740 | 0.300 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 67 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 130 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 75 | 0.260 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 98 | 0.250 |
Why?
|
| Radiation Injuries | 2 | 2016 | 51 | 0.240 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 1268 | 0.240 |
Why?
|
| Microtubules | 2 | 2016 | 89 | 0.230 |
Why?
|
| Cell Survival | 5 | 2017 | 395 | 0.230 |
Why?
|
| Benzodiazepinones | 2 | 2014 | 13 | 0.230 |
Why?
|
| Adenocarcinoma | 4 | 2017 | 288 | 0.230 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 658 | 0.220 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 16 | 0.220 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 31 | 0.210 |
Why?
|
| Humans | 21 | 2024 | 27115 | 0.200 |
Why?
|
| Hepatocytes | 2 | 2020 | 75 | 0.190 |
Why?
|
| RNA, Messenger | 5 | 2015 | 648 | 0.190 |
Why?
|
| Cell Movement | 5 | 2020 | 353 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 1496 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2020 | 36 | 0.180 |
Why?
|
| beta Catenin | 1 | 2020 | 62 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 251 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 114 | 0.170 |
Why?
|
| Receptor, Notch1 | 3 | 2017 | 26 | 0.160 |
Why?
|
| Gene Expression | 3 | 2015 | 408 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 131 | 0.160 |
Why?
|
| Intestines | 2 | 2016 | 117 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2016 | 111 | 0.150 |
Why?
|
| Stromal Cells | 2 | 2015 | 60 | 0.150 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 7 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 15 | 0.140 |
Why?
|
| Male | 6 | 2024 | 13019 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 149 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2015 | 705 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 30 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 34 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.130 |
Why?
|
| Pectins | 1 | 2015 | 7 | 0.130 |
Why?
|
| Mucositis | 1 | 2015 | 7 | 0.130 |
Why?
|
| Radiation-Protective Agents | 1 | 2015 | 22 | 0.120 |
Why?
|
| Stilbenes | 1 | 2016 | 90 | 0.120 |
Why?
|
| DNA Damage | 1 | 2016 | 149 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2015 | 31 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2015 | 66 | 0.120 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 7 | 0.120 |
Why?
|
| Female | 6 | 2024 | 14633 | 0.120 |
Why?
|
| Focal Adhesions | 1 | 2015 | 14 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2015 | 241 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 13 | 0.120 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 116 | 0.120 |
Why?
|
| Mice, Nude | 4 | 2018 | 313 | 0.120 |
Why?
|
| Biomarkers | 2 | 2016 | 738 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 462 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2013 | 46 | 0.110 |
Why?
|
| Virus Replication | 1 | 2013 | 63 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2014 | 121 | 0.110 |
Why?
|
| Wound Healing | 1 | 2014 | 113 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 143 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2015 | 398 | 0.110 |
Why?
|
| Indoles | 1 | 2013 | 98 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 144 | 0.100 |
Why?
|
| Carcinogenesis | 2 | 2024 | 76 | 0.100 |
Why?
|
| Esophagus | 1 | 2012 | 69 | 0.090 |
Why?
|
| Middle Aged | 3 | 2024 | 6899 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 70 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 1405 | 0.090 |
Why?
|
| Aged | 2 | 2024 | 5221 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2024 | 264 | 0.090 |
Why?
|
| RNA Interference | 3 | 2015 | 135 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2016 | 278 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2015 | 108 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 489 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 133 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2016 | 506 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 325 | 0.080 |
Why?
|
| RNA-Binding Proteins | 3 | 2014 | 83 | 0.080 |
Why?
|
| 5'-Nucleotidase | 1 | 2008 | 13 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2018 | 794 | 0.080 |
Why?
|
| Adenosine | 1 | 2008 | 33 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 97 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2011 | 276 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2020 | 53 | 0.070 |
Why?
|
| Endotoxemia | 1 | 2006 | 8 | 0.070 |
Why?
|
| Protein C | 2 | 2006 | 38 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 279 | 0.070 |
Why?
|
| Hemostasis | 1 | 2006 | 47 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 109 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 310 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 119 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 195 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 305 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 763 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2024 | 51 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 440 | 0.050 |
Why?
|
| Adult | 1 | 2015 | 7490 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 42 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2013 | 198 | 0.050 |
Why?
|
| Blood Coagulation Factors | 1 | 2002 | 31 | 0.050 |
Why?
|
| Phospholipids | 1 | 2002 | 75 | 0.050 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 28 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 40 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 62 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 58 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 32 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 118 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2015 | 512 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 127 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 156 | 0.040 |
Why?
|
| Genes, APC | 1 | 2017 | 14 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 411 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 119 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 42 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 28 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2016 | 41 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 68 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2008 | 156 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 155 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 65 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 46 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 72 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2015 | 35 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 988 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 567 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 129 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 285 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 313 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2014 | 6 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 129 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 21 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 59 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 49 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 37 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 16 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 43 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 50 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2014 | 47 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 29 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2014 | 86 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 253 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 205 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 60 | 0.030 |
Why?
|
| Adenoma | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 30 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 107 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2013 | 20 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 149 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 139 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 455 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 667 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 331 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 221 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 341 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 147 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 472 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 818 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 976 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 636 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 59 | 0.020 |
Why?
|
| Dipeptides | 1 | 2011 | 22 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 53 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 76 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1570 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1219 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 151 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 481 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2453 | 0.020 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2008 | 1 | 0.020 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2008 | 2 | 0.020 |
Why?
|
| Venules | 1 | 2008 | 3 | 0.020 |
Why?
|
| L-Selectin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2008 | 7 | 0.020 |
Why?
|
| Adenosine Monophosphate | 1 | 2008 | 20 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 243 | 0.020 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2006 | 6 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 58 | 0.020 |
Why?
|
| Heterozygote | 1 | 2006 | 64 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 73 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2008 | 142 | 0.020 |
Why?
|
| Thrombin | 1 | 2006 | 68 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 147 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2006 | 467 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2002 | 45 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 96 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 129 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 218 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 408 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 445 | 0.010 |
Why?
|